Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium cromoglycate, quantity: 1 mg - inhalation, pressurised - excipient ingredients: apaflurane; macrogol 600; povidone - the prophylactic treatment of bronchial asthma, including the prevention of exercise induced bronchospasm.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium cromoglycate, quantity: 5 mg - inhalation, pressurised - excipient ingredients: povidone; macrogol 600; apaflurane - the prophylactic treatment of bronchial asthma, including the prevention of exercise induced bronchospasm.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 17 dagu; poliovirus, quantity: 20 dagu; poliovirus, quantity: 5 dagu - injection, suspension - excipient ingredients: sodium hydroxide; hydrochloric acid; formaldehyde solution; phenoxyethanol; glucose monohydrate; purified water; polysorbate 80; ascorbic acid; sodium chloride; aminobenzoic acid; adenosine phosphate; dl-alpha-tocopheryl phosphate disodium; magnesium sulfate; monobasic potassium phosphate; deoxyribose; calcium chloride dihydrate; iron trinitrate; potassium chloride; magnesium sulfate heptahydrate; potassium nitrate; sodium selenite; monobasic sodium phosphate; dibasic sodium phosphate heptahydrate; adenine sulfate; adenosine triphosphate disodium; cholesterol; glutathione; guanine hydrochloride; hypoxanthine; phenolsulfonphthalein; ribose; sodium acetate; thymine; uracil; xanthine; sodium pyruvate; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; hydroxyproline; isoleucine; asparagine; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. ipol should be offered to patients who have refused opv or in whom opv is contraindicated. ipol is also indicated for: 1) the primary vaccination of immunocompromised individuals of all ages, and household contacts of such individuals (when vaccination is indicated); (2) unvaccinated or inadequately vaccinated(*) adults, particularly if at increased risk of exposure to live polio virus, including: - travellers to areas or countries where poliomyelitis is epidemic or endemic: - laboratory workers handling specimens which may contain polio virus; - health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who may not have completed a primary series of vaccination or not received a booster dose since infancy. idications as at 9 june 2003: ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommen

Европейский союз - английский - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drugs used in diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - ascorbic acid, quantity: 150 mg; zinc gluconate, quantity: 45 mg (equivalent: zinc, qty 6.5 mg); sodium ascorbate, quantity: 112.5 mg (equivalent: ascorbic acid, qty 100 mg) - tablet, chewable - excipient ingredients: magnesium stearate; hypromellose; maize starch; silicon dioxide; microcrystalline cellulose; glucose monohydrate; sucralose; maltodextrin; ascorbic acid; purified water; acacia; soya oil; dunaliella salina; citric acid; sucrose; mixed (low-alpha type) tocopherols concentrate; flavour

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - ascorbic acid, quantity: 500 mg; zinc gluconate, quantity: 14 mg (equivalent: zinc, qty 2 mg); echinacea purpurea, quantity: 22.22 mg (equivalent: echinacea purpurea, qty 1000 mg); allium sativum, quantity: 8.33 mg (equivalent: allium sativum, qty 100 mg) - tablet, film coated - excipient ingredients: povidone; magnesium stearate; hypromellose; macrogol 400; vanillin; garlic bulb powder; dl-alpha-tocopherol; maize starch; silicon dioxide; croscarmellose sodium; crospovidone; microcrystalline cellulose; calcium hydrogen phosphate dihydrate

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - insulin aspart, quantity: 3.5 mg/ml - injection, solution - excipient ingredients: metacresol; phenol; polysorbate 20; sodium hydroxide; hydrochloric acid; water for injections; zinc chloride; sodium chloride - for the treatment of diabetes mellitus

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; histidine hydrochloride monohydrate; sucrose; polysorbate 80; histidine - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - isatuximab, quantity: 100 mg - injection, concentrated - excipient ingredients: histidine; histidine hydrochloride monohydrate; polysorbate 80; sucrose; water for injections - sarclisa is indicated:,? in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).,? in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Филиппины - английский - FDA (Food And Drug Administration)

n/a; importer: sanofi-aventis philippines, inc.; distributor: sanofi-aventis philippines, inc. - ambroxol hydrochloride - syrup - 30 mg/ 5 ml